Physician profile
Patrick Tang
NPI 1316109739
$6,572.48
in general payments reported to CMS, 2019-2025
62 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $342 · 2021: $504 · 2022: $1,288 · 2023: $801 · 2024: $1,119 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,389 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,388.66 |
| Education | $205.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $631.87 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals Lp | $561.39 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $534.46 | 2019-2025 | |
| Pfizer INC. | $522.62 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $487.63 | 2019-2025 | Opdivo |
| Amgen INC. | $422.87 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Incyte Corporation | $315.11 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Astellas Pharma US INC | $314.88 | 2019-2025 | Padcev, Xospata, Vyloy |
| Janssen Biotech, INC. | $284.56 | 2019-2025 | Erleada, Tecvayli, Darzalex |
| Genentech USA, INC. | $218.17 | 2021-2025 | Tecentriq, Itovebi, Rozlytrek |
| Abbvie INC. | $187.14 | 2019-2025 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $151.38 | 2022-2025 | Ninlaro, Fruzaqla, Iclusig |
| Eisai INC. | $144.84 | 2019-2025 | |
| Celgene Corporation | $132.06 | 2019-2025 | Reblozyl, Sprycel |
| Genzyme Corporation | $119.99 | 2019-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.